Aim: Obese subjects are characterized by increased high-sensitivity C-reactive protein (hsCRP) and coronary vascular resistance. Clucocorticoids suppress inflammation, a possible cardioprotective effect. We tested the short-term anti-inflammatory effect of dexamethasone (dx) on these parameters in obese subjects. Methods: Coronary vascular resistance was quantitated basally and during adenosine infusion with or without simultaneous euglycemic hyperinsulinemic clamp (insulin infusion rate of 1 mU/kg/min) in 11 obese and 19 age-matched nonobese males using positron emission tomography and 15 O-water. Each subject was studied both with and without previous dx treatment for 2 days (2 mg/day). Results: Before dx treatment, hsCRP concentration was significantly higher in obese than in nonobese subjects (1.5571.73 vs 0.3270.32 mg/l, P ¼ 0.005). In addition, coronary vascular resistances were higher (Po0.05) in obese than in nonobese subjects at baseline (139736 vs 117722) and during adenosine infusion without (3277 vs 2677) or with simultaneous clamp (2678 vs 2175 mmHg min g/ ml). Dx treatment decreased significantly hsCRP concentration in obese but not in nonobese subjects, leading to similar hsCRP concentrations between the groups (0.4570.43 vs 0.2670.42 mg/l, respectively, P ¼ 0.3). Dx had no effect on coronary vascular resistances (NS). Conclusions: Obese subjects are characterized by high hsCRP, which can be normalized by dx. However, despite this, coronary vascular resistances did not decrease in obese subjects. Short-term changes in inflammatory response protein appear not to parallel with changes in coronary vasoreactivity in obese men.
Introduction
Recently, the American Heart Association has classified obesity as a major risk factor for coronary artery disease. 1 A body mass index (BMI) greater than 28 kg/m 2 is associated with a three to four times higher risk of morbidity from stroke or coronary artery disease than that of the general population. 2 As the prevalence of obesity is reaching epidemic proportions in Western countries, 3 this serious public health problem has been the subject of intensive study.
Atherosclerosis is an inflammatory process. Epidemiological studies have demonstrated that high-sensitivity Creactive protein (hsCRP), an inflammatory response protein, predicts future coronary events in apparently healthy subjects. 4 HsCRP is found to associate with BMI. 5 Recently, endothelial function has been demonstrated to correlate with visceral body fat, which is a key regulator site for the process of inflammation. 6 In obese subjects, weight loss, 5 insulin sensitizers 7, 8 and statins 9, 10 reduce hsCRP concentrations. More importantly, weight loss is also associated with the improvement of endothelial function in obese subjects. 6 In addition, to monitor the ongoing inflammatory process, CRP may be directly related to the development of atherosclerosis. 11 Thus, inflammatory response appears to be important in the development of coronary artery disease in obese subjects.
As differences in the vasoreactivity between coronary and peripheral arteries have been observed, previous studies targeting hsCRP effects on the skeletal muscle vasculature cannot be directly applied to the coronary vasculature. 12 It is known that obese subjects are characterized by reduced coronary vasodilatory function. 13, 14 However, although increased hsCRP concentrations are especially known to be associated with coronary events, studies addressing the effects of hsCRP on myocardial perfusion have not been performed in obese subjects. In addition, the effects of medication on hsCRP have been usually investigated after at least several weeks of treatment but the short-term effects have not been studied. Positron emission tomography (PET) imaging is currently the most accurate technique to quantify myocardial blood flow and coronary vascular resistance noninvasively. Coronary vascular resistance has been shown to become increased in the presence of coronary artery disease risk factors. 15 Furthermore, reduced coronary vasoreactivity can be improved by medical interventions. 16, 17 Clucocorticoids suppress secretion of inflammatory cytokines [18] [19] [20] and some animal studies have demonstrated beneficial effects of glucocorticoids during myocardial ischemia. 21, 22 Still, clucocorticoids appear not to benefit patients undergoing coronary artery bypass grafting. 19 However, since clucocorticoids have been found to increase shunt flow, 19 these antiinflammatory agents might have acute cardiovascular effects. In the present PET study, we examined the short-term anti-inflammatory effect of dexamethasone (dx) on hsCRP concentrations and coronary vascular resistance values in obese subjects. We used two different vasodilators, adenosine and insulin. The coronary vascular resistance response induced by adenosine reflects a combined effect of endothelium-dependent and -independent vasodilation, 23 whereas insulin induces and enhances vasodilation mainly via the endothelium-dependent mechanism. 24, 25 Coronary vascular resistance was measured before and after dx treatment at the baseline and during adenosine infusion with or without simultaneous euglycemic hyperinsulinemic clamp using PET and oxygen- 
Research methods and procedures

Subjects
Characteristics of the study subjects are shown in Table 1 . In all, 11 obese men who were otherwise healthy were investigated. The results of the obese subjects were compared with results of 19 age-matched nonobese healthy men. All subjects were nonsmoking, asymptomatic and had a history of normal blood pressure (BP), glucose and lipid values. None of the studied subjects had any medication. Echocardiographically determined left ventricular mass, dimensions and function as well as the stress echocardiographies and electrocardiograms were normal in all studied subjects.
Study design
Each subject was studied on two separate days, once after the administration of dx for 2 days (0.5 mg Â 4/day) with the last dose of dx on the morning of the PET study and once without dx. The two PET study days were performed in random order. All PET studies were performed after an overnight fast. Additionally, the subjects were instructed to avoid all caffeine-containing drinks and foods for 12 h before the PET studies. On each study day myocardial perfusion was measured three times (Figure 1 ), first at rest and secondly after administration of adenosine (140 mg/kg per min for 5 min intravenously). Thereafter, physiological hyperinsulinemia (1 mU/kg/min) 26 was started and continued for 60 min before the second intravenous infusion of adenosine hsCRP and coronary vasoreactivity J Sundell et al and the third perfusion measurement. The insulin infusion was continued until the third perfusion measurement was performed. Electrocardiogram and heart rate were monitored continuously during the studies. BP was monitored with an automatic oscillometric BP monitor (OMRON HEM-705C, Omron Healthcare, Hamburg, Germany) during the PET study. Each subject gave written, informed consent. The study was conducted according to the guidelines of the Declaration of Helsinki, and the study protocol was accepted by the Ethics Committee of the Turku University Central Hospital.
Insulin infusion
Insulin and glucose were infused in a catheter inserted in the right antecubital vein. The left hand was kept in a heated pillow and arterialized venous blood was withdrawn from a heated left antecubital vein. Insulin (Actrapid Human; Novo Nordisk, Copenhagen, Denmark) was infused at a rate of 1 mU/kg/min. Normoglycemia was maintained using a variable rate of 20% glucose. The rate of the glucose infusion was adjusted according to plasma glucose determinations performed every 5 min from arterialized venous blood. Samples for serum insulin and free fatty acids (FFAs) were taken every 30 min. Whole body glucose uptake was calculated from the glucose infusion rate after correcting for changes in the glucose pool size. way. 27 15 O-labelled water was produced using dialysis techniques in a continuously working water module. 28 Sterility and pyrogenity tests for water and chromatographic analysis for gases were performed to verify the purity of the products.
Image acquisition, processing and corrections
The subjects were positioned supine in a 15-slice ECAT 931/ 08-12 tomograph (Siemens/CTI Inc., Knoxville, TN, USA). After the transmission scan, the subjects' nostrils were closed and they inhaled [ 15 O]CO (B2.5 GBq) for 2 min through a three-way inhalation flap valve (0.14% CO mixed with room air). After the inhalation, 2 min were allowed for CO to combine with hemoglobin in red blood cells before a static scan for 4 min was started. During the scan period, three blood samples were drawn at 2-min intervals and blood radioactivity was measured immediately with a well counter (Bicron 3MW3/3, USA). A 10-min period was allowed for [ injected intravenously and dynamic scanning was started for 6 min (6 Â 5, 6 Â 15, 8 Â 30 s). All data were corrected for deadtime, decay and photon attenuation and reconstructed into a 128 Â 128 matrix. The final in-plane resolution in reconstructed and Hann-filtered (0.3 cycles/s) images was 9.5 mm (full-width half-maximum).
Calculation of regional myocardial blood flow and coronary vascular resistance Regions of interest (ROIs) were drawn in the lateral and anterior wall of the left ventricle in four representative transaxial slices in each study, as previously described. 29 The
ROIs outlined in the baseline images were copied to the images obtained after adenosine administration. Values of regional myocardial blood flow (expressed in ml/g of tissue per minute) were calculated according to the previously published method using the single-compartment model. 30 The arterial input function was obtained from the left ventricular time activity curve using a previously validated method, 31 in which corrections were made for the limited recovery of the left ventricular ROI and the spillover from the myocardial signals. No regional differences were found in myocardial perfusion. Therefore, to enhance accuracy and statistics of the flow measurements, the average blood flow of the lateral and anterior wall of the left ventricle was calculated and used in further analysis. As obese subjects had higher BP values than nonobese subjects, coronary vascular resistances, which take into account differences in BPs, were calculated. The coronary vascular resistance values were calculated both at basal and after adenosine with or without simultaneous insulin infusions by dividing the mean arterial BP by the respective flow value.
Echocardiographic examination
To rule out silent ischemia and cardiomyopathy, study subjects underwent a rest and a bicycle exercise echocardiographic examination. All echocardiographic recordings and analyses were performed by the same experienced investigator (ML) using a commercially available ultrasound scanner (Acuson 128XP/10, Acuson Inc., Mountain View, CA, USA). Standard echocardiographic views of the left ventricle were obtained and cardiac dimensions were measured first at rest. Thereafter, an upright bicycleergometer exercise test was performed by increasing workload by 20 W at 1-min intervals. The test was a symptom-limited maximal exercise test and continued until extreme fatigue when at least 90% of the predicted maximum heart rate was reached. The echocardiograms were recorded before and immediately after the exercise. All subjects had a normal exercise capacity, were asymptomatic, had no diagnostic ST changes in electrocardiograms and no wall motion disturbances either at rest or immediately after the maximal exercise.
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Analytical methods
Venous blood samples were taken after a 12-h overnight fast. Serum hsCRP was measured using a latex-enhanced immunoturbidimetric method (Wide Range C-Reactive Protein kit with Advia 1650, Bayer Diagnostics, USA). During insulin infusion, plasma glucose was determined by the glucose oxidase method. 32 Serum insulin was measured by radioimmunoassay kit (Pharmacia, Uppsala, Sweden). Plasma norepinephrine was measured at rest and after adenosine in every step, as previously described. 33 Serum total cholesterol, high-density lipoprotein cholesterol and triglyceride concentrations were measured using standard enzymatic methods (Boehringer Mannheim GmbH, Mannheim, Germany) with a fully automated analyzer (Hitachi 704; Hitachi Ltd, Tokyo, Japan). The low-density lipoprotein cholesterol concentration was calculated using the Friedewald formula. 34 Apolipoprotein A-1 (apo A-1) and apolipoprotein B (apo B) was measured by an immunonephelometric method (Behring BNA, Marburg, Germany). The serum lipoprotein(a) (Lp[a]) were determined using a solid-phase two-site immunoradiometric assay (Mercodia Apo(a) RIA; Mercodia AB, Uppsala, Sweden). glycosylated hemoglobin A 1c was measured with the high-pressure liquid chromatography.
Statistical methods
The results are expressed as mean7s.d. The effect of dx treatment on vascular resistance and flow values between the two study days, the responses to adenosine infusion with and without hyperinsulinemia, and the interaction of these variables were tested using repeated measures analysis of variance (procedure Mixed in Statistical Analysis System, SAS Institute Inc., Cary, NC, USA). For correlation analysis, Pearson's correlation coefficients were calculated. Paired and unpaired t-tests were used when appropriate. P-values less than 0.05 were interpreted as statistically significant. All statistical tests were performed with the SAS statistical analysis system (SAS Institute Inc., Gary, NC, USA).
Results
hsCRP
Serum hsCRP values are shown in Figure 2 . Before dx treatment, hsCRP concentrations were significantly higher than in obese than nonobese subjects (Po0.01). Dx treatment decreased significantly hsCRP concentrations in obese but not in nonobese subjects, leading to similar hsCRP concentrations between the groups (NS between the groups).
Coronary vascular resistance and myocardial blood flow Coronary vascular resistance values are shown in Figure 3 . Before dx treatment, coronary vascular resistances were higher in obese than in nonobese subjects (Po0.05). Dx treatment had no significant effect on coronary vascular resistances in obese or nonobese subjects (dxÀ vs dx þ , NS). No significant correlation existed between hsCRP and coronary vascular resistances before or after dx treatment in obese or nonobese subjects. Before dx treatment, no significant differences were detected in myocardial blood flow values between obese and nonobese subjects at baseline (0.870. and with simultaneous hyperinsulinemic clamp before (dxÀ) and after (dx þ ) dexamethasone treatment in obese and nonobese subjects. For comparison, basal coronary vascular resistance before dexamethasone treatment was 139736 and 117722 mmHg min g/ml for obese and nonobese, respectively, Po0.05 between the groups and after dexamethasone treatment was 138731 and 127738 mmHg min g/ml for obese and nonobese, respectively, NS between the groups. hsCRP and coronary vasoreactivity J Sundell et al without (3.470.7 and 3.571.3) or with simultaneous clamp (3.770.9 and 4.671.5 ml/g/min).
Metabolic and hormonal characteristics
Metabolic and hormonal characteristics are shown in Table 2 . At the fasting state plasma glucose, serum insulin and FFA concentrations were similar in the studied groups on the two study days. During clamp, serum insulin and FFA concentrations were higher in obese than nonobese subjects before dx. After dx treatment, plasma glucose was lower but serum FFA concentrations were higher during the clamp in obese than in nonobese subjects. Insulin-stimulated whole body glucose uptake values were lower in obese than in nonobese subjects before and after dx treatment (Po0.05). Dx treatment reduced insulin-stimulated whole body glucose uptake by about 50% in both groups (Po0.05; Table 2 ).
Fasting serum cortisol concentration was 3467107 nmol/l in obese and 3197109 nmol/l in nonobese subjects (NS between the groups). After dx treatment, serum cortisol concentrations were o20 nmol/l in all of the studied subjects (dxÀ vs dx þ , Po0.001; NS between the groups). No differences were detected in fasting plasma norepinephrine concentrations between the groups before dx treatment (1.370.4 vs 1.470.5 nmol/l, obese vs nonobese; NS). Dx treatment decreased fasting plasma norepinephrine values significantly in both groups (1.070.3 vs 1.270.3 nmol/l, respectively; dxÀ vs dx þ , Po0.05; NS between the groups).
Hemodynamic measurements during PET Hemodynamic measurements during PET study are given in Table 3 . Obese subjects had higher BP and rate-pressure product values than nonobese subjects (Po0.05). Adenosine administration induced significant increase in heart rate and rate-pressure products both basally and during hyperinsulinemia in the studied groups. Dx treatment did not significantly change the hemodynamic parameters except that resting systolic BP increased in nonobese subjects and both resting heart rate and adenosine-stimulated ratepressure product during clamp decreased in obese subjects (Table 3) .
Discussion
In the present study, we demonstrated that obese subjects who were otherwise healthy are characterized by increased hsCRP and coronary vasoreactivity J Sundell et al hsCRP concentrations and coronary vascular resistance values. More importantly, we showed a novel finding that short-term anti-inflammatory treatment with dx normalizes hsCRP concentrations in obese subjects. However, coronary vascular resistance values remained unaltered after dx treatment. Consistent with previous studies, obese subjects of the present study were characterized by increased hsCRP concentrations and coronary vascular resistance values. Many studies have shown that obese subjects have high serum hsCRP concentration. 5, 9, [35] [36] [37] Insulin resistance in obese subjects appears to impair endothelial function, 38 which promotes adherence of leukocytes to the vessel wall and induces an inflammatory response. 39 In addition, obesity is associated with macrophage accumulation in adipose tissue. 40 Adipose tissue releases interleukin-6, which in turn stimulates the liver to produce increased quantities of Creactive protein. 41 Thus, excess adiposity could also increase CRP expression directly. Coronary vasodilatory function has been found to be reduced in obese subjects measured using intracoronary acetylcholine 13 and systemic adenosine infusion. 14 As reduced coronary vasoreactivity seems to be one of the earliest abnormalities in the development of coronary artery disease, 42 the increased coronary vascular resistance in obese subjects of the present study might indicate that these subjects are at increased risk of future cardiovascular events.
In the present study, we demonstrated a novel finding that dx treatment for 2 days normalizes increased hsCRP concentrations in obese subjects. In nonobese healthy subjects, dx had no effect on hsCRP concentrations, perhaps because these subjects had no risk factors for atherosclerosis. Previous studies have reported the reduction of hsCRP in obese subjects after energy restriction and weight loss on very-low-fat diets, 5 insulin sensitizers 7, 8 and statins. 9, 10 In addition, fibrates decrease the concentration of plasma acute-phase proteins 43 and the reduction associated with the use of aspirin in the risk of a first myocardial infarction appears to be directly related to the level of hsCRP. 4 Thus, it is possible that the beneficial effects of these medications are at least partly mediated via the anti-inflammatory mechanisms. However, previous studies have usually been performed after at least several weeks of treatment, whereas we demonstrated in the present study that hsCRP could be reduced in 2 days. In the present study, dx administration offered an experimental model to study the short-term effect of decreased hsCRP on coronary vascular function in obese subjects. To specifically study this topic, the obese subjects of the present study had no other diseases such as diabetes or coronary artery disease, which are known to further increase coronary vascular resistance. We found that although dx treatment for 2 days normalized hsCRP concentrations, coronary vascular resistance values remained unaltered in obese subjects. This indicates that the short-term suppression of atherosclerotic low-grade inflammation does not decrease coronary vascular resistance values in obese subjects.
In a recent PET study, no association was found between hsCRP, adhesion molecule, Chlamydia pneumoniae antibody concentrations and adenosine-stimulated coronary vasodilation in healthy adults. 44 Concordantly, we did not find a correlation between coronary vascular resistance and hsCRP concentrations in obese or nonobese subjects. In patients who are undergoing cardiac surgery, acute administration of methylprednisolone reduces postoperative interleukin-6 secretion but offers no clinical benefits. [18] [19] [20] However, in the peripheral vasculature, normalization of elevated hsCRP concentrations over time is associated with a normalization of endothelium-mediated flow after 3 months in patients with coronary artery disease. 45 Thus, in the present study dxinduced anti-inflammatory period for 2 days might be too short to improve coronary vascular resistance in obese subjects. On the other hand, it is possible that the role of hsCRP in the blunted vasoreactivity is different between the peripheral and cardiac vasculature indicating the complexity of the regulation of coronary arteries. Further studies are needed to investigate the effect of long-term anti-inflammatory treatment on coronary vasoreactivity in obese subjects. Although high costs and limited availability prevent the wider use of the method, PET enables noninvasive, quantitative and accurate measurements of coronary vasoreactivity in humans. 15 In the present study, the coronary vasoreactivity was measured during adenosine infusion with or without simultaneous hyperinsulinemic clamp. Approximately half of the adenosine-induced vasodilation is endothelium dependent 23 and therefore adenosine is an integrating measure of endothelial function and vascular smooth muscle relaxation. In contrast to resting condition where flow and myocardial work (oxygen consumption) are tightly coupled, during adenosine stimulation, metabolic control of myocardial blood flow is lost but endothelial and neurogenic controls are still functional. In addition, the flow is directly dependent on BP and modulated by mechanical forces in the myocardial wall. 46 Insulin induces and enhances vasodilation mainly via the endothelium-dependent mechanism. 24, 25 Thus, in the present study, adenosine-stimulated coronary vascular resistance values were lower during the clamp. In the present study, myocardial blood flow values were not significantly reduced in obese subjects when compared to nonobese subjects. This is explained by the difference in BP levels between the groups. Coronary vascular resistance, which takes into account differences in BPs, was significantly higher in obese subjects. In previous studies in humans short-term dx treatment, despite the decrease in insulin sensitivity, has been found to have no effects on coronary flow values in healthy subjects. 47 In the present study, the significant difference in basal and adenosine-stimulated coronary vascular resistances between obese and nonobese subjects was abolished by dx. Dx is known to block centrally mediated sympathetic activation. 48 No differences were found in plasma norepinephrine concentrations before and after dx treatment between the groups. Still, we cannot rule out the possibility hsCRP and coronary vasoreactivity J Sundell et al that some metabolic effect of dx or other unmeasured mechanism might have an effect on coronary resistances in the present study. However, adenosine-stimulated flow during clamp was significantly blunted in obese subjects also after dx treatment. This might be at least partly explained by the fact that in obese subjects a defect in coronary vasodilation appears to be more dominantly endothelium dependent than -independent 13 and insulin is known to induce and enhance vasodilation mainly via the endothelium-dependent mechanism. 24, 25 In summary, the present data demonstrate that obese subjects are characterized by high hsCRP concentrations, which can be normalized by dx. However, despite this, coronary vascular resistance values did not decrease in obese subjects. Thus, short-term changes in inflammatory response protein appear not to parallel with changes in coronary vasoreactivity in obese men.
